Trial Profile
Canadian Advanced Parkinson DUODOPA-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence (CADENCE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Mar 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms CADENCE
- Sponsors AbbVie
- 10 Mar 2020 Status changed from active, no longer recruiting to completed.
- 17 Feb 2020 Planned End Date changed from 30 Apr 2021 to 1 Mar 2020.
- 17 Feb 2020 Planned primary completion date changed from 30 Apr 2021 to 1 Mar 2020.